Gujarat Themis Biosyn raises $60.6M in debt to fund Japan acquisition

What's the deal? Gujarat Themis BiosynDealroom has a profile for this one. Try Dealroom → has raised up to US$79.4M in a secured debt financing from EAAA India Alternatives and Avendus Finance Private LimitedDealroom has a profile for this one. Try Dealroom →. The company used the proceeds primarily to fund part of its acquisition of Micro Biopharm Japan Company LimitedDealroom has a profile for this one. Try Dealroom →.

What's the endgame? The financing bankrolls Gujarat Themis Biosyn's push into Japan through the Micro Biopharm deal. It extends the Indian biopharmaceutical firm's reach beyond its home market.

Who advised? Cyril Amarchand MangaldasDealroom has a profile for this one. Try Dealroom → acted as counsel to the investors. Its team was led by partners Abhijeet Das, regional head of financial services, and Abhishek Khatri.

The signal: The round ranks in the 92nd percentile by size among all-time debt financings in India's health sector, based on a sample of 62 deals. That scale signals growing investor appetite for debt-funded, cross-border expansion by Indian biopharma companies.

Read more: legaleraonline.com

Image credit: Generated with Gemini